POST-TEST

5-Minute Journal Club: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following descriptions best represents the design of the DARE trial?**
   a. A prospective, observational trial evaluating circulating tumor DNA (ctDNA) activity in patients receiving adjuvant endocrine therapy (ET) for localized breast cancer
   b. An interventional study in localized breast cancer evaluating therapeutic switching to fulvestrant/palbociclib versus continuing adjuvant ET for patients with positive ctDNA test results
   c. An interventional study evaluating therapeutic switching to camizestrant during first-line treatment for patients with advanced breast cancer found to have an ESR1 mutation in ctDNA test results
   d. An interventional study in localized breast cancer evaluating therapeutic switching to elacestrant versus continuing adjuvant ET for patients with positive ctDNA test results

2. **Which of the following statements best characterizes ctDNA dynamics in patients with detectable ctDNA at baseline in the DARE study?**
   a. Rates of ctDNA clearance were higher for patients who continued standard therapy
   b. Rates of ctDNA clearance were higher for patients who underwent therapeutic switching
   c. Rates of ctDNA clearance were approximately identical in the 2 treatment arms

3. **Which of the following descriptions best represents the design of the SIGNAL-ER 101 study?**
   a. An observational study evaluating ctDNA dynamics in patients with HER2-positive breast cancer receiving adjuvant trastuzumab/pertuzumab
   b. An interventional randomized study evaluating the addition of maintenance palbociclib to trastuzumab/pertuzumab/ET according to ctDNA status for patients with HR-positive, HER2-positive metastatic breast cancer
   c. A prospective registry study evaluating ctDNA surveillance with delayed initiation of adjuvant CDK4/6 inhibition for patients with HR-positive, HER2-negative breast cancer

4. **Which of the following statements is true regarding patients with localized breast cancer who had residual disease after surgery in the I-SPY2 trial?**
   a. ctDNA test results were nearly always positive for these patients
   b. Outcomes were markedly worse among patients with positive ctDNA test results than among those with cleared or baseline negative ctDNA test results
   c. ctDNA status was not prognostic of outcome for these patients